NASDAQ: COGTCogent Biosciences Inc Stock
$8.89-0.10 (-1.11%)
Updated Dec 6, 2024
COGT Price
$8.89
Fair Value Price
$0.43
Market Cap
$982.00M
52 Week Low
$3.67
52 Week High
$12.61
P/E
-3.58x
P/B
3.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$242.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$191M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COGT Overview
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COGT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
D
Growth
C
Momentum
D
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COGT
Ranked#389 of 554
Ranked#389 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.45 | A | |
| $6.72 | A | |
| $19.82 | A |
Be the first to know about important COGT news, forecast changes, insider trades & much more!
COGT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COGT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COGT ($8.89) is overvalued by 1,960.04% relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COGT ($8.89) is not significantly undervalued (1,960.04%) relative to our estimate of its Fair Value price of $0.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COGT due diligence checks available for Premium users.
Valuation
COGT fair value
Fair Value of COGT stock based on Discounted Cash Flow (DCF)
Price
$8.89
Fair Value
$0.43
Overvalued by
1,960.04%
COGT ($8.89) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COGT ($8.89) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COGT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.58x
Industry
-105.55x
Market
29.86x
COGT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.12x
Industry
5.68x
COGT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COGT's financial health
Profit margin
Revenue
$0.0
Net Income
-$70.6M
Profit Margin
0%
COGT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$384.0M
Liabilities
$69.4M
Debt to equity
0.22
COGT's short-term assets ($341.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COGT's short-term assets ($341.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COGT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COGT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$52.0M
Investing
$60.2M
Financing
$624.0k
COGT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COGT vs Biotech Stocks
Cogent Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.